Molecular predictors of survival after adjuvant chemotherapy for colon cancer

New England Journal of Medicine

Volumn 344, Issue 16, 2001, Pages 1196-1206

  Watanabe, Toshiaki ^a   Wu, Tsung Teh ^a   Catalano, Paul J ^b,f   Ueki, Takashi ^a   Satriano, Robert ^a   Haller, Daniel G ^c,f   Benson III, Al B ^d,f   Hamilton, Stanley R ^a,e,f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f Eastern Cooperative Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; PROTEIN P21; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 17P; CHROMOSOME 18Q; CHROMOSOME 8P; COLON CANCER; CONTROLLED STUDY; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 18; CHROMOSOMES, HUMAN, PAIR 8; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENETIC MARKERS; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RISK; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 0035912144     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200104193441603     Document Type: Article

References (78)

1. Cancer statistics, 2000
2. New adjuvant therapy for colon cancer: Justified hope or commercial hype
3. Adjuvant therapy of colon cancer
4. Current status of adjuvant chemotherapy for colorectal cancer: Can molecular markers play a role in predicting prognosis?
5. Molecular prognostic markers and colorectal cancer: The search goes on
6. Sequence of molecular genetic events in colorectal tumorigenesis
7. The genetic basis of colorectal cancer: Insights into critical pathways of tumorigenesis
8. Genetic instabilities in human cancers
9. DNA mismatch repair and cancer
10. Mismatch repair defects in cancer
11. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer
12. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines
13. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
14. Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences
15. Tumour markers of prognosis in colorectal cancer
16. Allelic loss of chromosome 18q and prognosis in colorectal cancer
17. Concordant p53 and DCC alterations and allelic losses on chromosomes 13q and 14q associated with liver metastases of colorectal carcinoma
18. Molecular genetics for clinical management of colorectal carcinomas: 17p, 18q, and 22q loss of heterozygosity and decreased DCC expression are correlated with the metastatic potential
19. Detection of DCC and Ki-ras gene alterations in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence
20. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator
21. Allelotype analysis of early colorectal cancers with lymph node metastasis
22. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer
23. Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer
24. Loss of heterozygosity at 18q 21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers
25. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
26. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis
27. Microsatellite instability in cancer of the proximal colon
28. Genomic instability in colorectal cancer: Relationship to clinicopathological variables and family history
29. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers
30. Replication error in colorectal carcinoma: Association with loss of heterozygosity at mismatch repair loci and clinicopathological variables
31. Microsatellite instability: Impact on cancer progression in proximal and distal colorectal cancers
32. Prognostic significance of DNA replication errors in young patients with colorectal cancer
33. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer
34. Does p53 status influence tumor response to anticancer therapies?
35. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
36. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study
37. p53 Gene mutation, microsatellite instability and adjuvant chemotherapy: Impact on survival of 388 patients with Dukes' C colon carcinoma
38. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer
39. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report
40. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: Five-year final report of INT-0089
41. Microdissection and polymerase chain reaction amplification of genomic DNA from histological tissue sections
42. Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region
43. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms
44. WAF1/CIP1/SDI1gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction
45. Diagnostic microsatellite instability: Definition and correlation with mismatch repair protein expression
46. A National Cancer Institute Workshop on Microsatellite Instability for Cancer Detection and Familial Predisposition: Development of International Criteria for the Determination of Microsatellite Instability in Colorectal Cancer: Cancer Res., 58: 5248-5257, 1998
47. Nonparametric estimation from incomplete observations
48. Evaluation of survival data and two new rank order statistics arising in its consideration
49. Regression models and life-tables
50. Why is p53 protein stabilized in neoplasia? Some answers but many more questions?
51. The significance of allelic deletions and aneuploidy in colorectal carcinoma: Results of a 5-year follow-up study
52. Prognostic significance of allelic loss at chromosome 18q21 for stage II colorectal cancer
53. DCC: Is there a connection between tumorigenesis and cell guidance molecules?
54. The DCC protein - Neural development and the malignant process
55. Deleted in Colorectal Cancer (DCC) encodes a netrin receptor
56. UNC-40, a C. elegans homolog of DCC (Deleted in Colorectal Cancer), is required in motile cells responding to UNC-6 netrin cues
57. The DCC protein and prognosis in colorectal cancer
58. DCC protein as a predictor of distant metastases after curative surgery for rectal cancer
59. Expression of DCC protein in colorectal tumors and its relationship to tumor progression and metastasis
60. Decreased expression of DCC mRNA in human colorectal cancers
61. The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis
62. The p53 tumor suppressor gene: From molecular biology to clinical investigation
63. p53 And cell-cycle control: A finger in every pie
64. Regulation of tumor cell apoptotic sensitivity during the cell cycle
65. The p53 pathway and cancer therapy
66. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
67. Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex
68. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins
69. Cip/WAF1Sdi1
70. The functions of the cdk-cyclin kinase inhibitor p21WAF1
71. p21/WAF1/CIP1 Expression in normal mucosa and in adenomas and adenocarcinomas of the colon: Its relationship with differentiation
72. Immunohistochemical expression of p53, bcl-2, mdm2, and waf1/p21 proteins in colorectal adenocarcinomas
73. Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinoma
74. Role of transforming growth factor β in human disease
75. Genetic events and the role of TGF beta in epithelial tumour progression
76. Mismatch repair proficiency and in vitro response to 5-fluorouracil
77. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer